Heat Biologics, Inc. Expands Product Development Team to Support Development of Lead Product Candidates in Oncology
GlobeNewswire - Tue Dec 02, 7:00AM CST
Heat Biologics, Inc. ("Heat"
HTBX: 4.18 (-0.22)
Heat Biologics, Inc. to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2 in New York
GlobeNewswire - Mon Dec 01, 7:01AM CST
Heat Biologics, Inc. ("Heat"
HTBX: 4.18 (-0.22)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 4.18 (-0.22), BIB: 122.51 (+3.83), INCY: 71.57 (+1.99), PFE: 31.42 (-0.03), IBB: 299.80 (+5.12), DRGS: 53.60 (unch), BIND: 5.73 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), ONTY: 1.89 (+0.01), ECYT: 6.33 (+0.24), BIS: 47.26 (-1.74), CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), ARIA: 6.81 (+0.15), IRY: 47.28 (-0.01), IXJ: 100.54 (+0.55), FPRX: 26.12 (+0.07)
Heat Biologics Q3 results
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:07AM CST
HTBX: 4.18 (-0.22)
Heat Biologics misses by $0.04
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:35AM CST
HTBX: 4.18 (-0.22)
Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results
GlobeNewswire - Fri Nov 14, 6:30AM CST
Heat Biologics, Inc. ("Heat"
HTBX: 4.18 (-0.22)
Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HTBX: 4.18 (-0.22), TNGO: 12.98 (unch), ENPH: 14.38 (-0.02), PRSC: 37.50 (+0.70), MTRX: 21.75 (-0.05), EPZM: 17.71 (+0.01), CHUY: 19.28 (-0.19), AMRI: 15.19 (+0.05), ANDE: 55.10 (+0.35), SNMX: 5.95 (+0.34), ZU: 23.81 (+0.25)
Heat Biologics Takes a New Approach to Immunotherapy
ACCESSWIRE - Mon Nov 03, 1:01PM CST
WHITEFISH, MT / ACCESSWIRE / November 3, 2014 / Immunotherapy leverages the body's own immune system to fight off diseases ranging from allergies to cancer. For example, Dendreon Corporation's (NASDAQ: DNDN) PROVENGE therapy takes the patient's own immune cells and reprograms them to attack advanced prostate cancer. These dynamics led to a 22.5% reduced risk of death with just a 1.5% discontinuance rate.
HTBX: 4.18 (-0.22), DNDN: 0.13 (-0.02), NLNK: 39.08 (+1.36), GALE: 1.49 (-0.02)
Heat Biologics starts patient dosing in bladder cancer trial
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 12:07PM CDT
HTBX: 4.18 (-0.22)
Heat Biologics, Inc. Commences Patient Dosing of Phase 2 Clinical Study of Vesigenurtacel-L for the Treatment of Bladder Cancer
GlobeNewswire - Mon Oct 27, 7:05AM CDT
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it has initiated patient dosing in its Phase 2 clinical trial of vesigenurtacel-L (HS-410) in subjects with high-risk, non-muscle invasive bladder cancer. Vesigenurtacel-L is Heat's investigational drug in a series of proprietary Immune Pan Antigen Cytotoxic Therapy ("ImPACT"
HTBX: 4.18 (-0.22)
Heat Biologics Completes Dosing for Vesigenurtacel-L Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 2:54PM CDT
Heat Biologics, Inc. (HTBX) recently announced that it has dosed the ninth and final patient required for the phase I part of its phase I/II clinical study on experimental biologic candidate, vesigenurtacel-L (HS-410).
HTBX: 4.18 (-0.22), SHPG: 209.29 (+0.07), SCMP: 13.75 (+0.44), PCRX: 92.09 (-1.79)
Heat Biologics, Inc. Completes Enrollment of Phase 1 Clinical Trial of Vesigenurtacel-L for the Treatment of Bladder Cancer Required to Advance to Phase 2
GlobeNewswire - Thu Oct 02, 6:35AM CDT
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it has dosed the ninth and final patient required in the Phase 1 portion of its Phase 1/2 clinical study for Vesigenurtacel-L (HS-410) in patients with high-risk non-muscle invasive bladder cancer. The Company expects to commence the Phase 2 portion of the bladder cancer clinical trial during the fourth quarter of 2014.
HTBX: 4.18 (-0.22)
Heat Biologics, Inc. to Present at the 13th Annual BIO Investor Forum in San Francisco on Tuesday, October 7, 2014
GlobeNewswire - Tue Sep 30, 6:30AM CDT
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting at the 13 Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will be held October 7-8, 2014 at the Palace Hotel in San Francisco, California.
HTBX: 4.18 (-0.22)
Heat Biologics Commences Patient Dosing in Phase 2 Study of Viagenpumatucel-L for the Treatment of Non-Small Cell Lung Cancer
GlobeNewswire - Thu Sep 18, 7:07AM CDT
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company"
HTBX: 4.18 (-0.22)
Heat Biologics, Inc. to Present and Webcast at Two Investor Conferences in September
GlobeNewswire - Thu Sep 04, 6:30AM CDT
- Rodman & Renshaw 16 Annual Global Investment Presentation on September 9, 2014 -
HTBX: 4.18 (-0.22)
Heat Biologics concludes up to USD7.5m secured term loan facility with Square 1 Bank
M2 - Tue Aug 26, 7:48AM CDT
Biopharmaceutical company Heat Biologics (NasdaqCM:HTBX) announced on Monday that it has completed a debt financing of up to USD7.5m with Square 1 Bank in four tranches based on the achievement of significant corporate milestones over the next 14 months.
HTBX: 4.18 (-0.22)
Heat Biologics, Inc. Closes on Up to $7.5 Million Secured Term Loan Facility
GlobeNewswire - Mon Aug 25, 7:29AM CDT
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it closed on a debt financing in the principal amount of up to $7.5 million with Square 1 Bank. Funds from the secured term loan will be utilized for working capital and to progress the Company's clinical trials and will be made available to the Company in four tranches based on the achievement of significant corporate milestones over the next 14 months. Following the closing of the loan, management expects the Company's current cash position to be extended by at least two quarters through the first quarter of 2016.
HTBX: 4.18 (-0.22)
Heat Biologics, Inc. Reports 2014 Second Quarter Financial Results
GlobeNewswire - Thu Aug 14, 6:05AM CDT
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company"
HTBX: 4.18 (-0.22)